Statement of Changes in Beneficial Ownership (4)
09 Juni 2020 - 12:50PM
Edgar (US Regulatory)
FORM 4
[X]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Invesco Ltd. |
2. Issuer Name and Ticker or Trading Symbol
Evofem Biosciences, Inc.
[
EVFM
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Last)
(First)
(Middle)
1555 PEACHTREE STREET NE, SUITE 1800 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/14/2020 |
|
(Street)
ATLANTA, GA 30309
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common stock | 5/14/2020 | | J(1) | | 78013 | A | $5.13 | 12446479 | I | See Footnotes 1 |
| Common stock | 5/15/2020 | | S | | 3211 | D | $5.04 | 12443268 | I | See Footnotes 1 |
| Common stock | 5/26/2020 | | S | | 73814 | D | $5.79 | 12369454 | I | See Footnotes 1 |
| Common stock | 5/26/2020 | | S | | 65 | D | $5.98 | 12369389 | I | See Footnotes 1 |
| Common stock | 6/5/2020 | | P(2)(3) | | 857143 | A | $3.50 | 13226532 | I | See Footnotes 2 |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Explanation of Responses: |
| (1) | Invesco Ltd. acquired the following common shares through its affiliates in a spin off transaction (the "Spin Off Transaction") on May 14, 2020: Invesco FTSE RAFI US 1500 Small-Mid ETF (73,814 shares of common stock); Invesco Buyback Achievers ETF (3,257 shares of common stock); LongView Broad Market 3000 Index Fund (Amalgamated) (923 shares of common stock); and Invesco Purebeta MSCI USA Small Cap ETF (19 shares of common stock). On May 15, 2020 the Invesco Buyback Achievers ETF sold 3,211 shares of Common Stock. On May 26, 2020, the Invesco FTSE RAFI US 1500 Small-Mid ETF sold 73,814 shares of Common Stock, the Invesco Buyback Achievers ETF sold 46 shares of Common Stock and the Invesco Purebeta MSCI USA Small Cap ETF sold 19 shares. |
| (2) | On June 5, 2020, Invesco Ltd., through its affiliates, the Invesco High Income Fund (UK) and the Invesco Income Fund (UK), purchased 589,302 and 267,841, respectively, of the Issuer's common stock at a price of $3.50 per share as part of the Issuer's registered public offering of 28,500,000 shares. |
| (3) | Invesco Ltd. is aware that, under Section 16(b) of the Securities and Exchange Act of 1934, as amended, certain of the sales are matachable against certain purchases of Common Stock. Invesco Ltd. has calculated the aggregate profit to be $174,140.20, using the lowest possible purchase prices and the highest possible sales prices for such trades, and accordingly intends to remit payment to the Company in that amount less transaction costs. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Invesco Ltd.
1555 PEACHTREE STREET NE
SUITE 1800
ATLANTA, GA 30309 |
| X |
|
|
Signatures
|
| Robert Leveille, Global Assurance Officer | | 6/9/2020 |
| **Signature of Reporting Person | Date |
Evofem Biosciences (NASDAQ:EVFM)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Evofem Biosciences (NASDAQ:EVFM)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
